This is an observational study performed by retrospective review of data routinely collected for patients receiving low-flow extracorporeal carbon dioxide removal (ECCO2R) therapy in intensive care units (ICUs). Our aim is to firstly, describe the local practice in terms of patient selection and technical details of clinical management related to the use of low-flow ECCO2R system, and secondly, the clinical results in terms of patient outcomes and adverse events. These findings may allow clinicians to improve the quality and safety of ECCO2R therapy provision in the ICU.
Patients supported with ECCO2R in one of the designated study sites
Admitted to the ICU between 1 Jan 2022 and 30 June 2024
Patients younger than 18 years old
Patients supported with ECCO2R in our designated study sites
Cohort
Retrospective
Not listed
Around 60 participants with respiratory failure as assessed for their clinical characteristics and outcomes
The primary endpoint is to describe the patients' demographics (e.g. Age, Sex), clinical characteristics (e.g. APACHE score, ventilator using time, respiratory parameters, ventilatory parameters, Mortality), outcomes of patients (death or survive) who received ECCO2R therapy. The secondary endpoints are to evaluate the association between clinical factors and patient outcomes (e.g. life of stay in ICU, ventilator free days), and to identify potential risk factors for adverse events and complications.
Click on the lead sponsor to view all of their trials.
Hong Kong University
Lead sponsor
Hospital Authority, Hong Kong
Sponsor institution
